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Abstract Elevated cardiac troponin-I (cTnI) levels have
been demonstrated in serum of patients without acute
coronary syndromes, potentially via a stretch-related pro-
cess. We hypothesize that this cTnI release from viable
cardiomyocytes is mediated by stimulation of stretch-
responsive integrins. Cultured cardiomyocytes were treated
with (1) Gly–Arg–Gly–Asp–Ser (GRGDS, n=22) to stim-
ulate integrins, (2) Ser–Asp–Gly–Arg–Gly (SDGRG, n=8)
that does not stimulate integrins, or (3) phosphate-buffered
saline (control, n=38). Cells and media were analyzed for
intact cTnI, cTnI degradation products, and matrix metal-
loproteinase (MMP)-2. Cell viability was examined by
assay of lactate dehydrogenase (LDH) activity and by
nuclear staining with propidium iodide. GRGDS-induced
integrin stimulation caused increased release of intact cTnI
(9.6±3.0%) as compared to SDGRG-treated cardiomyo-
cytes (4.5±0.8%, p<0.001) and control (3.0±3.4%,
p<0.001). LDH release from GRGDS-treated cardiomyo-
cytes (15.9±3.8%) equalled that from controls (15.2±2.3%,
p=n.s.), indicating that the GRGDS-induced release of cTnI
is not due to cell necrosis. This result was confirmed by
nuclear staining with propidium iodide. Integrin stimulation
increased the intracellular and extracellular MMP2 activity
as compared to controls (both p<0.05). However, despite
the ability of active MMP2 to degrade cTnI in vitro,
integrin stimulation in cardiomyocytes was not associated
with cTnI degradation. The present study demonstrates that
intact cTnI can be released from viable cardiomyocytes by
stimulation of stretch-responsive integrins.
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Introduction
Troponins are myofibrillar proteins involved in the regula-
tion of actin–myosin interaction, thereby controlling con-
traction and relaxation. Cardiac troponins (cTnT, cTnT, and
cTnC) are predominantly bound, via tropomyosin, to actin
filaments of sarcomeres, with only a small proportion of
cTnT (6–8%) and cTnI (3–8%) found in the soluble
cytoplasmic pool [1]. Due to high cardiac specificity, serum
concentrations of cTnI and cTnT are well-established
diagnostic and prognostic markers of irreversible myocar-
dial damage in acute coronary syndromes [9]. However,
elevated serum levels of cardiac troponins have also been
observed in patients without acute coronary syndromes in
whom irreversible myocardial cell injury was not a
prominent aspect [8, 11, 20]. Several studies reported
elevated serum levels of troponins in patients with
cardiomyopathy [29], heart failure [18], unstable angina
pectoris [14], pulmonary embolism [17], renal insufficiency
[5], and in ultra-endurance athletes [19]. The exact
mechanism underlying the release of troponins in the
absence of necrosis, without lethal disruption of the
sarcolemma, remains to be elucidated and most likely
differs from the release of troponins due to necrotic cell
death.
A potential explanation for the cTnI release without
lethal sarcolemmal disruption is the cellular release of
proteolytic cTnI degradation products. Indeed, in isolated
rat hearts, Feng et al. [6] showed degradation of cTnI upon
increasing preload, which was independent of ischemia.
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Mechanical stretch of cardiomyocytes, as occurs during
pressure or volume overload, initiates a cascade of
intracellular signals, including increased intracellular calci-
um concentration, increased intracellular NO formation,
and the activation of intracellular proteases such as MMP2
and MMP14 [28, 36]. MMP2 is able to degrade cTnI
intracellularly [39] and may be involved in the stretch-
induced release of cTnI and its degradation products. In
contrast, other studies suggest that cTnI leaks from
reversibly damaged cardiomyocytes as an intact non-
degraded molecule [8, 20].
Mechanical stretch of cardiomyocytes is sensed by
stimulation of integrins, which are transmembrane glyco-
protein receptors that link the extracellular matrix (ECM) to
the intracellular cytoskeleton [26]. Integrins act as mecha-
notransducers and bidirectional signaling molecules and
participate in overload-induced hypertrophic and post-
infarct remodeling [26]. The Arg–Gly–Asp (RGD)
sequence that is present in fibronectin and other ECM
proteins is an agonist for integrins [27], which can be used
to simulate myocardial mechanical stretch in vitro.
We hypothesize that the stretch-related process through
which cTnI can be released from viable cardiomyocytes
is mediated by integrin stimulation. The purpose of the
present study is therefore to investigate whether (1)
RGD-induced integrin stimulation causes release of intact
and/or fragmented cTnI from cardiomyocytes in the
absence of necrotic cell death, (2) integrin stimulation
is associated with MMP2 activation and MMP2-related
cTnI degradation, and (3) cTnI release in the absence of
necrosis differs from the release of cTnI in the presence
of necrosis.
Materials and methods
Primary cultures of neonatal cardiomyocytes
Primary cultures of cardiomyocytes were prepared from the
ventricles of 2-day-old Wistar rats as described previously
[24]. Briefly, ventricles were minced, and cells were
isolated enzymatically using collagenase type I (CLS,
Lakewood, NJ, USA) at 37°C. The cell suspension was
centrifuged, and the cell pellet was resuspended in growth
medium containing Ham’s F10 (Flow Laboratories, Irvine,
UK), 10% fetal bovine serum, 10% horse serum (HS),
100 U/ml penicillin, and 100 μg/ml streptomycin (all from
Invitrogen, Breda, The Netherlands). The cells were seeded
in 6-cm diameter Primaria®-coated plastic culture dishes
(Falcon, Becton Dickinson, Etten-Leur, The Netherlands),
and after 45 min, non-adherent cells representing the
cardiomyocytes were collected and plated in six-wells
plates (∅ 35 mm per well, Costar, Corning, NY, USA) at
a density of ≈1.5×10
6 cells per well. Cardiomyocytes were
incubated in a humidified incubator at 37°C and 5% CO2
and culture medium [1:1 (v/v) mixture of DMEM (Invi-
trogen) and Ham’s F10 supplemented with 5% HS,
penicillin (100 U/ml) and streptomycin (100 μg/ml)] was
refreshed after 20 h and 48 h. After 3 days of culturing, a
monolayer of spontaneously beating cardiomyocytes had
formed. The investigations had the approval of the Animal
Experiments Committee of the LUMC according to Dutch
law.
Experimental protocol for integrin stimulation
Three days after cell isolation, cardiomyocyte cultures were
washed twice in HEPES-buffered salt solution (HBSS),
containing (in millimole per liter) NaCl (125), KCl (5),
MgSO4 (1), KH2PO4 (1), CaCl2 (2.5), NaHCO3 (10),
D-glucose (5), HEPES (20), pH 7.4 at 37°C. Cardiomyo-
cytes were incubated for 24 h in 1 ml of HBSS
supplemented with (1) the pentapeptide Gly–Arg–Gly–
Asp–Ser containing the GRGDS sequence (Sigma, St.
Louis, MO, USA) at various concentrations (100, 200, or
300 μg/ml) to stimulate integrins, with (2) Ser–Asp–Gly–
Arg–Gly (SDGRG, the reverse sequence of GRGDS,
Sigma), which does not affect integrin function, at a
concentration of 300 μg/ml, or with (3) phosphate-buffered
saline (PBS) as a control. After 24 h, medium was
separated from the cells, cells were taken up in 1 ml of
ice-cold lysis buffer (100 mmol/l Tris–HCl, 0.1% Tween,
pH 7.5), both cell and medium samples were kept on ice
awaiting assay of lactate dehydrogenase (LDH) activity on
the same day, and subsequently stored at −20°C for later
cTnI and MMP2 assays.
Troponin-I ELISA
Purified human heart cTnI (Calbiochem, LaJolla, CA,
USA) was dissolved in urea/Tris buffer according to the
manufacturer’s instructions. Monoclonal mouse anti-cTnI
clone 19C7 (directed against amino acid sequence
40–50) and monoclonal mouse anti-cTnI clone 6F9
(directed against amino acid sequence 189-195) were
purchased from HyTest (Turku, Finland). The enzyme-
linked immunosorbent assay (ELISA) was based on the
sandwich principle as described previously [13]. The
percentage cTnI released from each culture equalled
TnImedium= TnImedium þ TnIcells ðÞ ½    100%. Detection limit
of the assay was 6 ng/ml. Inter-assay variability was 6 and
10% at a TnI concentration of 200 and 25 ng/ml,
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concentrations of 100 ng/ml.
Western blot analysis
Protein extracts were size-fractionated on NuPage Novex
12% Bis–Tris gels (Invitrogen) and transferred to Hybond
PVDF membranes (Amersham Biosciences, Roosendaal,
The Netherlands). Non-specific binding sites were blocked
using blocking solution consisting of 20 g/l ECL advance
blocking agent (Amersham Biosciences) in TBS-Tween
(10 mmol/l Tris–HCl, 150 mmol/l NaCl, 0.05% Tween
pH 8.0). Membranes were incubated for 1 h with the anti-
TnI antibody (K83085G, Biodesign, Saco, ME, USA),
which detects various cTnI degradation products. After four
washes in TBS-Tween, membranes were incubated with
horseradish peroxidase-labeled secondary antibody (rabbit
anti-goat IgG, Santa Cruz Biotechnology, Heidelberg,
Germany). Chemiluminescence was induced by ECL
advance detection reagent (Amersham Biosciences) and
detected by exposure to Hyperfilm ECL (Amersham
Biosciences).
LDH activity assay
Necrotic cell death was quantified by assay of LDH
activity released from cells into medium according to
Wroblewski and Ladue [41]. LDH activities of medium
and cell samples were determined using a spectrophoto-
meter (Ultrospec 3000, Pharmacia Biotech, Roosendaal,
The Netherlands) at 25°C. The total LDH activity in each
culture, i.e., cell+medium, was determined, and the LDH
activity in cell and medium samples was expressed as a
percentage of total LDH activity. The detection limit of the
LDH assay was 5 U/l, the intra-assay variability was 3%
(110 U/l) and 6% (48 U/l), and inter-assay variability was
12% (110 U/l).
Nuclear staining with propidium iodide
An additional assessment of cell death was performed by
quantifying the nuclei of necrotic cells using propidium
iodide and fluorescence microscopy. For this purpose,
cardiomyocyte cultures were treated with PBS, GRGDS,
and SDGRG for 24 h, then incubated with propidium iodide
(5 mg/l, Molecular Probes, Eugene, OR, USA) for 15 min
in the dark, washed in PBS, and viewed under a
fluorescence microscope (Zeiss, Hamburg, Germany) at
535/617-nm excitation/emission. Subsequently, cultures
were incubated with digitonine (10 μmol/l) for 5 min to
induce necrotic cell death in all cardiomyocytes. The extent
of necrosis equalled the number of necrotic nuclei before
digitonine incubation as a fraction of the number of necrotic
nuclei after digitonine incubation (100%).
In vitro degradation of purified cTnI by active MMP2
To study whether active MMP2 is able to degrade cTnI in
vitro, purified human cardiac TnI (500 pg/μl, Calbiochem)
was incubated with human recombinant active MMP2
(1.5 ng/μl, Oncogene, San Diego, CA, USA) in enzyme
buffer at 37°C for 0, 60, and 120 min. In a separate series of
experiments, MMP2 was preincubated with an inhibitor of
MMP2, o-phenanthroline (100 μmol/l) for 15 min. As a
control, cTnI was incubated without active MMP2 at 37°C.
Intact cTnI and cTnI degradation products were visualized
by Western blotting.
Zymography
Gelatinolytic activities of MMP2 in cell and medium
samples of control, GRGDS- and SDGRG-treated cardio-
myocytes were analyzed by zymography as described
previously [12, 33]. Briefly, cell samples (tenfold concen-
trated by freeze-drying for 18 h) and medium samples
(unconcentrated) were prepared in sample buffer and were
loaded on gels. After electrophoresis, the gels were washed
twice in 2.5% Triton X-100, were washed in enzyme buffer,
and were incubated in enzyme buffer at 37°C overnight.
Gels were stained with amino black and subsequently
destained. Gelatinase activity was quantified by measuring
the extent of gelatin digestion using a scanning densitom-
eter (2202 Ultrascan, LKB, Paramus, NJ, USA).
Experimental protocol for necrotic cell death
Three days after cell isolation, cardiomyocyte cultures were
washed twice in HBSS, pH 7.4, at 37°C, and subsequently
incubated in 1 ml of HBSS, supplemented with sodium
azide (1 mmol/l, n=7) at 37°C. After 24 h of incubation,
medium was separated from the cells, cells were taken up in
1 ml of ice-cold lysis buffer, both cell and medium samples
were kept on ice awaiting assay of lactate dehydrogenase
(LDH) activity on the same day, and subsequently stored at
−20°C for later cTnI assay.
Statistics
Results are expressed as mean±SD. Statistical analysis was
performed by Student’s t test and by one-way analysis of
variance followed by Bonferroni’s post hoc test. Differ-
Pflugers Arch - Eur J Physiol (2008) 455:979–986 981ences were regarded as statistically significant if p<0.05.
SPSS14 for Windows (SPSS, Chicago, IL, USA) was used
for statistical analysis.
Results
Effect of integrin stimulation on release of cTnI
Cell and medium samples were assayed for intact cTnI by
ELISA (Fig. 1a) and for cTnI degradation products using
Western blotting (Fig. 2a–d). Cellular cTnI content in ten
cultures was 0.27±0.10 μg per culture (100%). Control
cardiomyocytes had released ≈3% of total cTnI, probably as
a result of cell death of a few cardiomyocytes during 24 h
of incubation. GRGDS treatment at a concentration of 100
or 200 μg/ml did not show considerable release of cTnI
(≈2%). However, a concentration of 300 μg/ml GRGDS
resulted in a significant extra release of intact cTnI (to
≈10%), compared with control cardiomyocytes (p<0.001)
and cardiomyocytes treated with 100 or 200 μg/ml GRGDS
(both p<0.001; Fig. 1a). Incubation of cardiomyocytes with
300 μg/ml SDGRG, the reverse sequence of GRGDS that
has no effect on integrin function, did not induce a
significant extra release of intact cTnI (Fig. 1a). In addition,
Fig. 2b and d shows that cTnI was released as an intact
protein of 29 kDa and that integrin stimulation is not
associated with the release of cTnI degradation products.
Effect of integrin stimulation on cell viability
Necrotic cell death was quantified by the release of LDH
activity from cardiomyocytes into the medium (Fig. 1b).
Cellular LDH activity of ten cultures was 0.47±0.24 U per
culture (100%). In control cardiomyocytes, ≈15% of total
LDH was released in 24 h, which confirms previous
findings of cellular necrosis in cardiomyocytes after 24 h
in serum-free medium [25]. LDH release from integrin-
stimulated cardiomyocytes (GRGDS, 300 μg/ml) equalled
LDH release from control cardiomyocytes (Fig. 1b).
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Fig. 1 a Release of cardiac troponin-I (cTnI) from cardiomyocytes
incubated with PBS (control, n=38), GRGDS (100 μg/ml, n=5;
200 μg/ml, n=4; 300 μg/ml, n=22), or SDGRG (300 μg/ml, n=8),
detected by ELISA. b Release of LDH from cardiomyocytes
incubated with PBS (control, n=38), GRGDS (300 μg/ml, n=22), or
SDGRG (300 μg/ml, n=8). (*p<0.001 vs control,
#p<0.001 vs
GRGDS 100,
$p<0.001 vs GRGDS 200,
‡p<0.001 vs GRGDS 300,
and
§p<0.001 vs SDGRG 300)
Fig. 2 Western blots of intact cTnI (29 kDa) and cTnI degradation
products present in cell samples (left, 2.5× diluted) and medium
samples (right, 10× concentrated) of cardiomyocytes incubated with
PBS (control), GRGDS (300 μg/ml, a and b), SDGRG (300 μg/ml, c
and d), or sodium azide (1 mmol/l, e and f) for 24 h
982 Pflugers Arch - Eur J Physiol (2008) 455:979–986Surprisingly, cardiomyocytes treated with SDGRG (300
μg/ml) for 24 h showed significantly less LDH release
(9.5%) than control and GRGDS-treated cardiomyocytes
(both p<0.001).
Assessment of cell death using nuclear staining with
propidium iodide showed a similar pattern. The percentage
of necrotic cells in controls (7.2±2.1%, n=8) equalledthat of
GRGDS-treated cardiomyocytes (8.5±2.2%, n=8, p=N.S.).
Again, the percentage of necrotic cells in SDGRG-treated
cardiomyocytes was significantly lower (6.2±1.9%, n=8)
compared with GRGDS-treated cardiomyocytes (p<0.05),
confirming the results of the LDH assay.
These results demonstrate that integrin stimulation by
GRGDS participates in the release of cTnI from cardio-
myocytes in the absence of necrosis.
Effect of integrin stimulation on MMP2 activity
In control experiments, we verified that recombinant active
MMP2 is able to degrade purified cTnI in vitro in a number
of fragments of 26, 14 and 8 kDa (Fig. 3). However, as we
observed no cTnI degradation upon integrin stimulation
(Fig. 2), we studied whether this was due to the lack of
MMP2 activation during integrin stimulation, measuring
the zymographic gelatinolytic activities of MMP2. In
control cardiomyocytes, gelatinolytic MMP2 activities were
detected in both cell and medium samples, indicating a
baseline level of MMP2 in cultured cardiomyocytes
(Fig. 4). Total MMP2 levels were higher in medium than
in cells (≈90 vs ≈10% of total MMP2, respectively).
In cells samples, several gelatinolytic activities of
MMP2 were detected corresponding to a rodent-specific
glycosylated MMP2 (75 kDa), proMMP2 (72 kDa, the
major gelatinase activity), an active intermediate MMP2
(64 kDa), and active MMP2 (62 kDa; Fig. 4, left). GRGDS-
treated cardiomyocytes demonstrated significantly higher
levels of cellular proMMP2 (72 kDa) and active MMP2
(64+62 kDa) than control and SDGRG-treated cardio-
myocytes (Fig. 4, left), whereas levels of glycosylated
MMP2 (75 kDa) were unaffected by GRGDS. In medium
samples (Fig. 4, right), several gelatinolytic activities of
MMP2 were detected, corresponding to a rodent-specific
glycosylated MMP2 (75 kDa), proMMP2 (72 kDa), and
active MMP2 (62 kDa), respectively. GRGDS-induced
integrin stimulation resulted in significantly higher medium
levels of glycosylated MMP2 (75 kDa) and active MMP2
(62 kDa) compared to medium samples of control and
SDGRG-treated cardiomyocytes (both p<0.05; Fig. 4,
right). Medium levels of proMMP2 (72 kDa) were
unaffected by integrin stimulation.
Release of cTnI from necrotic cardiomyocytes
To compare the release of cTnI from viable cardiomyocytes
during GRGDS-induced integrin stimulation with the
release of cTnI upon necrotic cell death, cardiomyocyte
cultures were treated with sodium azide (1 mmol/l) to
induce necrotic cell death. After 24 h of azide-treatment,
LDH release from cardiomyocytes was 73.4±10.5% (n=7),
indicating extensive necrotic cell death. Release of intact
cTnI from these necrotic cardiomyocytes was 32.7±13.8%
(n=7). Notably, in contrast to the release of intact cTnI
from integrin-stimulated cardiomyocytes (Fig. 2b), cardio-
myocyte necrosis leads to the release of at least four cTnI
degradation products with molecular weights of 26, 20, 17,
and 12 kDa (Fig. 2f).
Discussion
The major findings of this study are that integrin stimula-
tion in cardiomyocytes by GRGDS leads to (1) release of
intact cTnI from viable cardiomyocytes in the absence of
necrosis and (2) increased levels of intracellular and
extracellular MMP2 activity that, however, does not result
in degradation of cTnI into its fragments. This study
therefore indicates that the release mechanism of cTnI from
viable cardiomyocytes upon integrin stimulation differs
from cTnI release from necrotic cardiomyocytes, which is
associated with extensive cTnI degradation.
Elevated plasma cTnI levels are frequently found in
pathological conditions in which irreversible myocardial
cell injury is not a prominent aspect. In patients with
heart failure, elevated plasma cTnI levels have been
reported with normal plasma levels of CK-MB [2, 18].
Some studies have suggested that elevated serum levels of
cTnI may be the result of myocardial strain [15, 20], as
occurs during pressure or volume overload. Logeart et al.
[15] studied 71 patients with heart failure and found in 19
patients elevated cTnI concentrations associated with LV
remodeling and increased plasma brain natriuretic peptide
Fig. 3 Western blot of intact cTnI (29 kDa) and cTnI degradation
products after in vitro incubation of purified intact cTnI without and
with active MMP2 and with active MMP2 in combination with a
MMP2 inhibitor (o-phenanthroline) for 0, 60, and 120 min
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have led to the increased cTnI release, but necrotic cell
death was not excluded in that study. In acute pulmonary
embolism, several reports showed elevated cTnI levels
[17, 21] possibly related to the presence of myocardial
strain. In addition, Feng et al. [6]d e m o n s t r a t e dt h a t
increased preload in isolated rat hearts was sufficient to
cause release of cTnI as the result of myocardial stretch
independent of ischemia.
Overload-induced stretch at the cardiomyocyte level is
sensed by integrins, mechanotransducers molecules that
link the extracellular matrix to the intracellular cytoskeleton
[32]. In the present study, we showed that GRGDS-induced
integrin stimulation of cardiomyocytes resulted in a
threefold increased release of cTnI that occurred in the
absence of necrosis, as cell viability remained unchanged
by GRGDS treatment compared with control cardiomyo-
cytes. Control cardiomyocytes demonstrated baseline levels
of necrosis after 24 h, consistent with previous findings of
cell death in cardiomyocytes after 24 h in serum-free
medium [25]. Surprisingly, we found significantly less
necrosis in SDGRG-treated cardiomyocytes than in control
cardiomyocytes with both LDH assay and nuclear staining
with propidium iodide. The mechanism responsible for this
protective effect is unlikely to be related to integrin function
but may be related to protection against necrosis exerted by
certain proteins such as serum components.
Several studies have suggested that release of cTnI from
viable cardiomyocytes, without lethal disruptions of the
cardiomyocyte sarcolemma, does not involve intact cTnI
(29 kDa) but rather proteolytic degradation products of
cTnI formed by intracellular proteases as MMP2 and
calpain-I [6, 7]. In the present study, we demonstrated that
purified intact cTnI can indeed be degraded by active
MMP2 in vitro. MMPs are a family of zinc-containing
enzymes involved in degradation of the extracellular matrix
during tissue remodeling [34]. However, MMP2 also acts
intracellularly and may, therefore, be responsible for
degradation of myofilament proteins including cTnI and
myosin light chain-1 (MLC-1) [30, 39]. MMPs are
synthesized by a variety of cells, including cardiomyocytes
[4], in a latent form (proMMP) that is activated by either
proteolytic cleavage or by conformational changes induced
by cytokines, reactive oxygen species, and peroxynitrite
[22, 35, 38]. Previously, Wang et al. [37] have demonstrat-
ed that mechanical stretch of neonatal cardiomyocytes
induced expression and activation of MMP2. In addition,
integrin stimulation by GRGDS has been reported to
upregulate MMP2 expression in fibroblasts and certain
tumor cell lines [31, 40], suggesting an important role for
integrins in regulating MMP2 activity. In the present study,
we showed that GRGDS-induced integrin stimulation of
cultured cardiomyocytes was indeed associated with in-
creased activity of intracellular proMMP2 and active
MMP2 and increased release of active MMP2 into the
medium. In cardiomyocytes incubated with SDGRG,
neither cellular levels nor medium levels of proMMP2 or
active MMP2 were altered compared to control cardiomyo-
cytes, indicating that increased MMP2 activity is specific
for GRGDS-induced integrin stimulation.
However, despite the increase of MMP2 activity during
integrin stimulation and the ability of active MMP2 to
degrade purified cTnI in vitro, integrin stimulation was not
associated with cTnI degradation. If cTnI degradation had
occurred, we would have been able to detect that in this
system (Figs. 3 and 2f). The reason for the lack of cTnI
Fig. 4 Gelatinolytic activities of
MMP2 isoforms in cell samples
(left, 10× concentrated) and
medium samples (right, uncon-
centrated) of cardiomyocytes
incubated with PBS (control,
n=12), GRGDS (300 μg/ml,
n≥9), or SDGRG (300 μg/ml,
n≥3) for 24 h
984 Pflugers Arch - Eur J Physiol (2008) 455:979–986degradation in the presence of GRGDS-induced MMP2
activation is unclear. The discrepancy between the in vitro
degradation of purified cTnI by active MMP2 and the lack
of cTnI degradation in GRGDS-treated cardiomyocytes
may be explained by a difference in specific MMP2
activity. The MMP2 activity per nanogram cTnI in the
study with purified cTnI was fourfold higher than that in
cardiomyocytes treated with RGD. In addition, purified
cTnI may be more susceptible to MMP2 cleavage than cTnI
that is complexed to cTnT, cTnC, and tropomyosin. In
cardiomyocytes, 93–97% of cTnI is complexed to cTnT,
cTnC, and tropomyosin which may protect the MMP2
cleavage sites on the cTnI molecule.
The mechanism responsible for the release of intact cTnI
from viable integrin stimulated cardiomyocytes may be
leakage of free intact cTnI from the cytosolic pool. Several
studies have demonstrated that mechanically induced
transient disruptions (wounding) of the sarcolemma are a
constitutive event in vivo [3, 10, 16, 23]. This mechanism
is responsible for the release of proteins, such as myocyte-
derived growth factors (fibroblast growth factors 1 and 2),
which are released despite the lack of a classic signal
peptide sequence normally associated with exocytotic
secretion. These mechanically induced alterations in
cardiomyocyte’s sarcolemmal permeability may similarly
be involved in the release of cTnI from the cytosolic pool of
cardiomyocytes in the absence of necrotic cell death.
Further study is needed to address this issue.
Conclusions
The present study demonstrates that viable cardiomyocytes
release cTnI as an intact protein by a stretch-related
mechanism mediated by integrins. This finding may
possibly explain why, in several pathological conditions,
plasma cTnI levels are elevated in the absence of
myocardial necrosis.
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